Brum, Wagner S. http://orcid.org/0000-0002-9777-0559
Cullen, Nicholas C.
Therriault, Joseph http://orcid.org/0000-0002-7826-4781
Janelidze, Shorena
Rahmouni, Nesrine
Stevenson, Jenna
Servaes, Stijn
Benedet, Andrea L.
Zimmer, Eduardo R. http://orcid.org/0000-0002-5349-0053
Stomrud, Erik
Palmqvist, Sebastian http://orcid.org/0000-0002-9267-1930
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Frisoni, Giovanni B.
Ashton, Nicholas J.
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
Mattsson-Carlgren, Niklas
Rosa-Neto, Pedro http://orcid.org/0000-0001-9116-1376
Hansson, Oskar http://orcid.org/0000-0001-8467-7286
Funding for this research was provided by:
Vetenskapsrådet (2022-00775)
Alzheimerfonden (AF-980907)
Article History
Received: 26 January 2023
Accepted: 4 March 2024
First Online: 14 March 2024
Competing interests
: J.S. has received research funding from Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly); consulted for Roche Pharmaceuticals, Biogen, Merck, and Eli Lilly; given educational lectures sponsored by GE Healthcare, Eli Lilly, and Biogen; and is Chief Medical Officer for ARUK. H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). N.J.A. has given lectures in symposia sponsored by Eli-Lilly, Roche Diagnostics, and Quanterix. N.J.A. has declined paid opportunities from ALZpath. K.B. has served as a consultant, on advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers and is a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Genentech, Merck, Novartis, Novo Nordisk, Roche, Sanofi, and Siemens. The remaining authors declare no competing interests.